Immuneering (IMRX) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

COVER PAGE

COVER PAGE - shares	9 Months Ended
	Sep. 30, 2024	Nov. 06, 2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-40675
Entity Registrant Name	Immuneering Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1976972
Entity Address, Address Line One	245 Main St
Entity Address, Address Line Two	Second Floor
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	500-8080
Title of 12(b) Security	Class A common Stock, par value $0.001 per share
Trading Symbol	IMRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001790340
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Class A Common Stock
Entity Common Stock, Shares Outstanding		31,050,448
Class B Common Stock
Entity Common Stock, Shares Outstanding		0

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 45,205,577	$ 59,405,817
Marketable securities	5,452,155	26,259,868
Prepaids and other current assets	4,601,769	3,417,984
Total current assets	55,259,501	89,083,669
Property and equipment, net	1,205,095	1,400,582
Goodwill	6,690,431	6,690,431
Intangible asset, net	357,730	379,680
Right-of-use assets, net	3,748,565	3,995,730
Other assets	1,295,782	1,034,446
Total assets	68,557,104	102,584,538
Current liabilities:
Accounts payable	1,942,782	2,111,666
Accrued expenses	4,592,825	5,173,960
Other liabilities	59,657	259,770
Lease liabilities	324,702	300,107
Total current liabilities	6,919,966	7,845,503
Long-term liabilities:
Lease liabilities, net of current portion	3,916,324	4,162,852
Total liabilities	10,836,290	12,008,355
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; 0 shares issued or outstanding at September 30, 2024 and December 31, 2023	0	0
Additional paid-in capital	263,925,619	253,806,267
Accumulated other comprehensive loss	7,845	(778)
Accumulated deficit	(206,243,700)	(163,258,578)
Total stockholders' equity	57,720,814	90,576,183
Total liabilities and stockholders' equity	68,557,104	102,584,538
Class A Common Stock
Stockholders’ equity:
Common stock	31,050	29,272
Class B Common Stock
Stockholders’ equity:
Common stock	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Class A Common Stock
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	31,050,448	29,271,629
Common stock, shares outstanding (in shares)	31,050,448	29,271,629
Class B Common Stock
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	0	0
Common stock, shares outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses
Research and development	$ 11,252,850	$ 10,050,198	$ 33,107,222	$ 29,713,835
General and administrative	4,013,581	3,868,823	12,384,074	12,375,114
Amortization of intangible asset	7,317	7,317	21,950	21,950
Total operating expenses	15,273,748	13,926,338	45,513,246	42,110,899
Loss from operations	(15,273,748)	(13,926,338)	(45,513,246)	(42,110,899)
Other income (expense)
Interest income	547,072	855,532	2,178,060	2,852,852
Other income, net	129,310	475,595	350,063	869,917
Net loss	$ (14,597,366)	$ (12,595,211)	$ (42,985,123)	$ (38,388,130)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.49)	$ (0.43)	$ (1.45)	$ (1.36)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.49)	$ (0.43)	$ (1.45)	$ (1.36)
Weighted-average common shares outstanding, basic (in shares)	29,841,883	29,266,309	29,622,670	28,129,005
Weighted-average common shares outstanding, diluted (in shares)	29,841,883	29,266,309	29,622,670	28,129,005
Other comprehensive income (loss):
Unrealized gains from marketable securities	$ 7,845	$ 7,825	$ 8,624	$ 35,727
Comprehensive Loss	$ (14,589,521)	$ (12,587,386)	$ (42,976,499)	$ (38,352,403)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($)	Total	Class A Common Stock	Class B Common Stock	Common Stock Class A Common Stock	Common Stock Class B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022				26,418,732	0
Beginning balance at Dec. 31, 2022	$ 109,850,255			$ 26,419	$ 0	$ 219,640,912	$ (30,120)	$ (109,786,956)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				77,065
Issuance of common stock upon exercise of stock options	239,409			$ 77		239,332
Stock-based compensation expense	1,273,505					1,273,505
Net loss	(13,604,171)							(13,604,171)
Other comprehensive income (loss)	30,626						30,626
Ending balance (in shares) at Mar. 31, 2023				26,495,797	0
Ending balance at Mar. 31, 2023	97,789,624			$ 26,496	$ 0	221,153,749	506	(123,391,127)
Beginning balance (in shares) at Dec. 31, 2022				26,418,732	0
Beginning balance at Dec. 31, 2022	109,850,255			$ 26,419	$ 0	219,640,912	(30,120)	(109,786,956)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(38,388,130)
Ending balance (in shares) at Sep. 30, 2023				29,269,121	0
Ending balance at Sep. 30, 2023	104,017,637			$ 29,269	$ 0	252,157,847	5,607	(148,175,086)
Beginning balance (in shares) at Mar. 31, 2023				26,495,797	0
Beginning balance at Mar. 31, 2023	97,789,624			$ 26,496	$ 0	221,153,749	506	(123,391,127)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				39,958
Issuance of common stock upon exercise of stock options	176,146			$ 40		176,106
Stock-based compensation expense	1,333,882					1,333,882
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs (in shares)				2,727,273
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs	27,996,235			$ 2,727		27,993,508
Net loss	(12,188,748)							(12,188,748)
Other comprehensive income (loss)	(2,724)						(2,724)
Ending balance (in shares) at Jun. 30, 2023				29,263,028	0
Ending balance at Jun. 30, 2023	115,104,415			$ 29,263	$ 0	250,657,245	(2,218)	(135,579,875)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				6,093
Issuance of common stock upon exercise of stock options	21,448			$ 6		21,442
Stock-based compensation expense	1,479,160					1,479,160
Net loss	(12,595,211)							(12,595,211)
Other comprehensive income (loss)	7,825						7,825
Ending balance (in shares) at Sep. 30, 2023				29,269,121	0
Ending balance at Sep. 30, 2023	104,017,637			$ 29,269	$ 0	252,157,847	5,607	(148,175,086)
Beginning balance (in shares) at Dec. 31, 2023		29,271,629	0	29,271,629	0
Beginning balance at Dec. 31, 2023	90,576,183			$ 29,272	$ 0	253,806,267	(778)	(163,258,578)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				229,299
Issuance of common stock upon exercise of stock options	732,458			$ 229		732,229
Issuance of common stock through employee stock purchase plan (in shares)				152,427
Issuance of common stock through employee stock purchase plan	247,465			$ 152		247,313
Stock-based compensation expense	1,474,758					1,474,758
Net loss	(14,307,829)							(14,307,829)
Other comprehensive income (loss)	(306)						(306)
Ending balance (in shares) at Mar. 31, 2024				29,653,355	0
Ending balance at Mar. 31, 2024	78,722,729			$ 29,653	$ 0	256,260,567	(1,084)	(177,566,407)
Beginning balance (in shares) at Dec. 31, 2023		29,271,629	0	29,271,629	0
Beginning balance at Dec. 31, 2023	$ 90,576,183			$ 29,272	$ 0	253,806,267	(778)	(163,258,578)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	229,299
Net loss	$ (42,985,123)
Ending balance (in shares) at Sep. 30, 2024		31,050,448	0	31,050,448	0
Ending balance at Sep. 30, 2024	57,720,814			$ 31,050	$ 0	263,925,619	7,845	(206,243,700)
Beginning balance (in shares) at Mar. 31, 2024				29,653,355	0
Beginning balance at Mar. 31, 2024	78,722,729			$ 29,653	$ 0	256,260,567	(1,084)	(177,566,407)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	1,661,749					1,661,749
Net loss	(14,079,927)							(14,079,927)
Other comprehensive income (loss)	1,084						1,084
Ending balance (in shares) at Jun. 30, 2024				29,653,355	0
Ending balance at Jun. 30, 2024	66,305,635			$ 29,653	$ 0	257,922,316	0	(191,646,334)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock through employee stock purchase plan (in shares)				78,341
Issuance of common stock through employee stock purchase plan	127,187			$ 78		127,109
Stock-based compensation expense	1,640,116					1,640,116
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs (in shares)				1,318,752
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs	4,237,397			$ 1,319		4,236,078
Net loss	(14,597,366)							(14,597,366)
Other comprehensive income (loss)	7,845						7,845
Ending balance (in shares) at Sep. 30, 2024		31,050,448	0	31,050,448	0
Ending balance at Sep. 30, 2024	$ 57,720,814			$ 31,050	$ 0	$ 263,925,619	$ 7,845	$ (206,243,700)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) (Parenthetical) - USD ($)		3 Months Ended
	Apr. 20, 2023	Sep. 30, 2024	Jun. 30, 2023
Underwriting Offering
Sale of stock, proceeds before deducting offering costs payable	$ 203,768	$ 86,374	$ 203,768

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (42,985,123)	$ (38,388,130)
Adjustment to reconcile to net loss to net cash used in operating activities:
Depreciation/amortization expense	269,691	233,062
Reduction in carrying amount of right-of-use assets	247,165	323,910
Intangible asset amortization	21,950	21,950
Stock-based compensation expense	4,776,623	4,086,547
Net accretion of discount on marketable securities	(203,491)	(613,952)
Loss on disposal of fixed assets	1,315	1,483
(Increase) decrease in:
Accounts receivable	0	12,417
Prepaid expenses and other current assets	(1,183,785)	(130,712)
Other assets	(261,337)	0
Increase (decrease) in:
Accounts payable	(168,884)	(1,277,464)
Accrued expenses	(581,135)	(1,224,216)
Lease liabilities	(221,934)	(299,029)
Other liabilities	(200,113)	60,701
Net cash used in operating activities	(40,489,058)	(37,193,433)
Cash flows from investing activities:
Purchases of property and equipment	(75,519)	(171,828)
Purchases of marketable securities	(5,410,170)	(28,914,599)
Maturities of marketable securities	26,430,000	33,250,000
Net cash provided by investing activities	20,944,311	4,163,573
Cash flows from financing activities:
Proceeds from exercise of stock options	732,458	437,003
Payment of offering costs	0	(203,768)
Net cash provided by financing activities	5,344,507	28,433,238
Net decrease in cash and cash equivalents	(14,200,240)	(4,596,622)
Cash and cash equivalents at beginning of period	59,405,817	72,636,886
Cash and cash equivalents at end of period	45,205,577	68,040,264
Supplemental disclosures of noncash information:
Property and equipment in accounts payable/accrued expenses	0	86,282
Employee Stock
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan	374,652	0
At the market offering
Cash flows from financing activities:
Proceeds from issuance of common stock	4,237,397	0
Public Offering
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 0	$ 28,200,003

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Organization and Nature of Business Immuneering Corporation, a Delaware corporation (“Immuneering” or the “Company”), was incorporated in 2008. Immuneering is a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients, with an initial aim to therapeutically address patients harboring RAS or RAF mutations. The Company aims to achieve universal RAS/RAF activity through Deep Cyclic Inhibition ("DCI"), of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate IMM-1-104, as well as its second product candidate IMM-6-415, are in Phase 1/2a clinical trials in patients with advanced solid tumors harboring RAS and RAS/RAF mutations, respectively. The Company is developing IMM-1-104 as a potential once-daily oral therapy that aims to achieve universal-RAS activity and IMM-6-415 with an accelerated twice-daily oral dosing cadence that aims to achieve universal-RAS/RAF activity, in each case through Deep Cyclic Inhibition of the MAPK pathway. The Company’s development pipeline also includes several early-stage programs. On October 30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (“ISC”), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company’s behalf. On December 22, 2021, the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (“BioArkive”), a California corporation, which as a result became a wholly owned subsidiary. Immuneering, ISC and BioArkive are collectively referred to as the “Company” throughout these condensed consolidated financial statements. The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company’s research and development programs will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants. On August 3, 2021, the Company completed its initial public offering (“IPO”) pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. On August 10, 2022, the Company entered into an Equity Distribution Agreement (the "Sales Agreement") with Piper Sandler & Co (the "Sales Agent"), to sell shares of its common stock with aggregate gross proceeds of up to $50 million, from time to time, through an “at the market” equity offering program ("ATM Program"). The Company sold 1,318,752 shares of common stock under the ATM Program, at an average price per share of $3.27, for aggregate gross proceeds of $4.5 million ($4.2 million net of offering expenses) during the three- and nine-months ended September 30, 2024. The Company did not sell any securities under the ATM Program during the three- and nine-months ended September 30, 2023. On April 20, 2023, the Company completed an underwritten follow-on equity offering, pursuant to which it issued and sold 2,727,273 shares of its Class A common stock $0.001 par value per share at an offering price of $11.00 per share. The aggregate net proceeds received by the Company from the offering were $28,200,003, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company of $203,768. Going Concern Assessment Management has assessed the Company’s ability to continue as a going concern in accordance with the requirements of ASC 205-40 Presentation of Financial Statements - Going Concern, taking into consideration its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future and the need to raise additional capital to finance future operations. To date, the Company has funded its operations through service revenues (which have since ceased), and with proceeds from the sale of its preferred stock, common stock and convertible notes, and through the exercise of stock options. The Company has incurred recurring losses since inception, including a net loss of $43.0 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had an accumulated deficit of $206.2 million. Based on its current cash expenditure forecast, the Company expects that its existing cash and cash equivalents will fund its operations into the fourth quarter of 2025.The interim condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The accompanying interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company expects to continue to generate operating losses in the foreseeable future. The Company will require additional funding through private or public equity financings, debt financings, collaborations, strategic transactions and/or licensing arrangements to remain in operation. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. If the Company is unable to obtain funding, the Company will be forced to incur restructuring costs, and the Company may be unable to continue operations. Management’s belief with respect to the Company's ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management’s estimates, the Company may need to seek additional funding sooner than would otherwise be expected. Based on these factors, as of November 13, 2024, the issuance date of the interim condensed consolidated financial statements for the three and nine months ended September 30, 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these interim condensed consolidated financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the condensed consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. There have been no material changes to the accounting policies of the Company as those set forth in Note 2 to the audited consolidated financial statements contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Unaudited Interim Financial Information The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with GAAP and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with GAAP have been omitted from the unaudited interim condensed consolidated financial statements, as is permitted by such rules and regulations. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2023. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, operating results and cash flows. Revenues and net loss for any interim period are not necessarily indicative of future or annual results. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these condensed consolidated financial statements include but are not limited to: the accrued research and development expenses, the determination of fair value of stock-based awards, and the impairment of goodwill and intangible assets. Actual results may differ materially and adversely from these estimates. Goodwill Goodwill represents the excess of the fair value of the acquiree over the recognized basis of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value. On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss. The Company performs its annual impairment test during the fourth quarter of each fiscal year. The Company performed an interim impairment analysis in the quarter ended June 30, 2024 as a result of the decline in market capitalization. Based on the step 1 analysis performed, the fair value of the reporting unit exceeded the carrying value on the valuation date and as a result there is no impairment pursuant to ASC 350 for the quarter ended June 30, 2024. There were no impairments identified for the year ended December 31, 2023 or for the three and nine months ended September 30, 2024 . Deferred Offering Costs The Company capitalizes certain legal, professional, and other third-party charges related to ongoing equity financings as deferred offering costs until fully consummated. These costs are to be recorded as a reduction of the offering’s proceeds which are recorded to additional paid-in capital within stockholders’ equity. Should the Company choose not to initiate such financing, the deferred offering costs would be immediately expensed as operating expenses. On August 10, 2022, the Company entered into an Equity Distribution Agreement (the “Sales Agreement”) with Piper Sandler & Co, (the “Sales Agent”) to sell shares of the Company’s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity offering program. Deferred offering costs associated with the Sales Agreement are reclassified to additional paid-in capital on a pro-rata basis when the Company completes offerings under the Sales Agreement. Any remaining deferred costs will be expensed to the statement of operations should the planned offering be abandoned. The Company had approximately $0.5 million of deferred offering costs as of September 30, 2024 and $0.3 million as of December 31, 2023. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt certain new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280) (“ASU 2023-07”). The guidance in ASU 2023-07 expands prior reportable segment disclosure requirements by requiring entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and details of how the CODM uses financial reporting to assess their segment’s performance. The standard is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating this standard's potential impact on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this effective January 1, 2024 and there was no impact to the condensed consolidated financial statements.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities Marketable securities consisted of the following as of September 30, 2024 and December 31, 2023, respectively: September 30, 2024 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Assets: Current: U.S. Treasuries $ 3,467,888 $ 3,157 $ — $ 3,471,045 Commercial paper 1,979,620 1,490 — 1,981,110 Total marketable securities $ 5,447,508 $ 4,647 $ — $ 5,452,155 December 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Assets: Current: U.S. Treasuries $ 2,989,460 $ 430 $ — $ 2,989,890 Government securities 15,342,582 888 (2,902) 15,340,568 Commercial paper 7,928,122 1,301 (13) 7,929,410 Total marketable securities $ 26,260,164 $ 2,619 $ (2,915) $ 26,259,868 Our marketable securities are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities and are recorded at fair value. Unrealized gains (losses) are included as a component of accumulated other comprehensive loss in the consolidated balance sheets and statements of stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the three and nine months ended September 30, 2024 or 2023. Realized gains and losses are included in other income (expense) on the consolidated statements of operations. Our marketable securities portfolio contains investments in U.S. Treasury, other U.S. government-backed securities, and commercial paper. We review our portfolio based on the underlying risk profile of the securities and we don't expect there to be a loss on these investments. We also regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three and nine months ended September 30, 2024 and 2023, we recognized no year-to-date credit loss related to our short-term investments, and had no allowance for credit loss recorded as of September 30, 2024 or December 31, 2023.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We record cash equivalents and marketable securities at fair value. ASC 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels: Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September 30, 2024: Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market $ 35,014,888 $ — $ — $ 35,014,888 U.S. Treasuries 1,748,407 — — 1,748,407 Government securities — 5,424,966 — 5,424,966 Commercial paper — 2,742,203 — 2,742,203 Total cash equivalents 36,763,295 8,167,169 — 44,930,464 Marketable securities: U.S. Treasuries $ 3,471,045 $ — $ — $ 3,471,045 Commercial paper — 1,981,110 — 1,981,110 Total marketable securities 3,471,045 1,981,110 — 5,452,155 Total cash equivalents and marketable securities $ 40,234,340 $ 10,148,279 $ — $ 50,382,619 There have been no changes to the valuation methods during the nine months ended September 30, 2024. There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the nine months ended September 30, 2024. Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our valuation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of September 30, 2024 and December 31, 2023. The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2023: Level 1 Level 2 Level 3 Total Assets: Cash equivalents U.S. Treasuries $ 3,488,205 $ — $ — $ 3,488,205 Money market 50,122,883 — — 50,122,883 Commercial paper — 2,494,670 — 2,494,670 Government securities — 2,981,550 — 2,981,550 Total cash equivalents 53,611,088 5,476,220 — 59,087,308 Marketable securities: U.S. Treasuries $ 2,989,890 $ — $ — $ 2,989,890 Commercial paper — 7,929,410 — 7,929,410 Government securities — 15,340,568 — 15,340,568 Total marketable securities 2,989,890 23,269,978 — 26,259,868 Total cash equivalents and marketable securities $ 56,600,978 $ 28,746,198 $ — $ 85,347,176

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net consisted of the following: September 30, December 31, Computer equipment $ 563,859 $ 550,861 Furniture and fixtures 98,628 98,628 Lab equipment 1,240,678 1,180,445 Leasehold improvements 298,941 298,941 Total 2,202,106 2,128,875 Accumulated depreciation/amortization (997,011) (728,293) Property and equipment, net $ 1,205,095 $ 1,400,582 Depreciation/amortization expense totaled $88,949 and $78,294 for the three months ended September 30, 2024 and 2023, respectively. Depreciation/amortization expense totaled $269,691 and $233,062 for the nine months ended September 30, 2024 and 2023, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Accrued Liabilities, Current [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consisted of the following: September 30, December 31, Accrued professional services $ 319,462 $ 297,160 Accrued employee expenses 2,701,878 3,625,911 Accrued research and development expenses 1,502,456 1,146,398 Accrued other 69,029 104,491 Total $ 4,592,825 $ 5,173,960

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Common Stock	Common Stock The Company had 200,000,000 authorized shares of Class A common stock, $0.001 par value per share as of September 30, 2024 and December 31, 2023 of which 31,050,448 and 29,271,629 were issued and outstanding, respectively. The holders of Class A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class B common stock. The Company had 20,000,000 authorized shares of Class B common stock, $0.001 par value per share as of September 30, 2024 and December 31, 2023, of which no shares have been issued nor are outstanding. The holders of Class B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class A common stock. Equity Offerings On August 10, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-266738) (the “2022 Shelf Registration Statement”) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units or any combination thereof in the aggregate amount of up to $200 million for a period of up to three years from the date of its effectiveness on August 19, 2022. On August 10, 2022, the Company also entered into the Sales Agreement with the Sales Agent to sell shares of the Company’s Class A common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity offering program (the “ATM Program”) under the 2022 Shelf Registration Statement. Subject to the terms and conditions of the Sales Agreement, the Sales Agent may sell the shares by methods deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act, including sales made through the Nasdaq Global Market, on any other existing trading market for the common stock, to or through a market maker, or, if expressly authorized by the Company, in privately negotiated transactions. The Company or Sales Agent may terminate the Sales Agreement upon notice to the other party and subject to other conditions. The Company will pay the Sales Agent a commission equal to 3.0% of the gross proceeds of any Common Stock sold through the Sales Agent under the Sales Agreement and has provided the Sales Agent with customary indemnification rights. The Company sold 1,318,752 shares of common stock under the ATM Program, at an average price per share of $3.27, for aggregate gross proceeds of $4.5 million ($4.2 million net of offering expenses) during the three- and nine-months ended September 30, 2024. The Company did not sell any shares under the ATM Program during the three and nine months ended September 30, 2023. Issuance costs incurred related to the Sales Agreement are classified as long-term assets on the balance sheet at September 30, 2024. The Company had approximately $0.5 million of deferred offering costs as of September 30, 2024 and $0.3 million as of December 31, 2023. On April 20, 2023, the Company completed an underwritten follow-on equity offering, pursuant to which it issued and sold 2,727,273 shares of its Class A common stock, $0.001 par value per share, at an offering price of $11.00 per share under the 2022 Shelf Registration Statement. The aggregate net proceeds received by the Company from the offering were $28,200,003, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company of $203,768.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Basic and diluted net loss per share attributable to common stockholders was calculated at September 30, 2024 and September 30, 2023 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator: Net loss $ (14,597,366) $ (12,595,211) $ (42,985,123) $ (38,388,130) Denominator - basic and diluted: Weighted-average common shares outstanding, basic and diluted 29,841,883 29,266,309 29,622,670 28,129,005 Net loss per share - basic and diluted $ (0.49) $ (0.43) $ (1.45) $ (1.36) The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at September 30, 2024 and September 30, 2023: 2024 2023 Options to purchase common stock 6,596,403 5,490,165 Total shares of common stock equivalents 6,596,403 5,490,165

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation During 2015, the Company established the Long Term Incentive Plan (“Incentive Plan”), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. Upon the effectiveness of the Company’s 2021 Incentive Award Plan (the “2021 Plan”), the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to govern awards outstanding thereunder. On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Plan, which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to 2,590,000 plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 4% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than 15,350,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or otherwise terminated. As of September 30, 2024, there were 1,388,539 shares available for future issuance under the 2021 Plan. On July 23, 2021, the Company’s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective on July 29, 2021. A total of 250,000 shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 1% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors, provided that not more than 3,340,000 shares of Class A common stock may be issued under the 2021 ESPP. As of September 30, 2024, there were 839,336 shares of common stock reserved for future issuance under the 2021 ESPP and 230,768 shares had been granted or purchased under the 2021 ESPP. On May 21, 2024 (the “Effective Date”), based upon the recommendation of the Compensation Committee (the “Committee”) of the Company's Board of Directors (the “Board”), the Board approved an option repricing, in accordance with the 2021 Plan, which repricing was effected on the Effective Date. The repricing applied to options to purchase shares of the Company’s Class A common stock with an exercise price per share greater than $3.01 that were held by current employees and certain non-employee service providers under the 2021 Plan (the “Eligible Options”). Options held by Benjamin Zeskind, Ph.D., the Company’s President and Chief Executive Officer, Brett Hall, Ph.D., the Company's Chief Scientific Officer and the non-employee members of the Board were not eligible for the repricing. As a result of the repricing, as of the Effective Date, the exercise price of all Eligible Options was reduced to $3.01 per share, which represents approximately two times the closing trading price of the Company’s Class A common stock on the Nasdaq Global Market on the Effective Date; however, the exercise price for repriced options will revert to the original exercise price for any exercise occurring prior to June 30, 2025 (the "Retention Period"), unless there is a change of control of the Company or the option holder’s employment has been terminated (i) by the Company without cause or (ii) by reason of death or disability. The repriced options otherwise remain subject to their existing terms and conditions as set forth in the 2021 Plan and applicable award agreements. As of the Effective Date, outstanding options to purchase 2,986,354 shares were deemed Eligible Options and were repriced such that the exercise price per share for such outstanding options was reduced to $3.01 per share. There were no changes to the number of shares, the vesting schedule or the expiration date of the Eligible Options. The effect of the repricing resulted in a total incremental non-cash stock-based compensation expense of $0.6 million, which was calculated using the Black-Scholes option-pricing model, of which $0.2 million of the incremental non-cash stock-based compensation expense is associated with vested repriced options and will be recognized on a straight-line basis through the 13-month Retention Period. The remaining $0.4 million of the incremental non-cash stock-based compensation expense is associated with unvested repriced options and will be recognized as follows: (a) if the Retention Period is greater than the remaining original vesting period of the repriced option, the incremental cost will be amortized on a straight-line basis through the Retention Period end date or (b) if the Retention Period is less than the remaining original vesting term of the repriced option, the incremental cost will be amortized on a straight-line basis over the remaining original vesting period. During the three and nine months ended September 30, 2024, the Company recognized incremental stock-based compensation expense of $84 thousand and $120 thousand, respectively, associated with the repricing which is included in general and administrative and research and development expense in the condensed consolidated statement of operations and comprehensive loss. The Company recognized stock-based compensation expense of $1,640,116 and $4,776,623 during the three and nine months ended September 30, 2024, respectively. During the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of $1,479,160 and $4,086,547, respectively. As of September 30, 2024, compensation expense remaining to be recognized for outstanding stock options was $11,544,508 and to be recognized over a weighted-average period of 2.28 years. The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. Prior to the Company’s IPO on August 3, 2021, the Company was a private company and thus lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded stock price. For the nine months ended September 30, 2024, the Company granted 1,530,445 shares of stock options at a weighted-average grant date fair value of $3.69. The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, 2024 2023 Weighted-average risk-free interest rate 3.93% - 4.82% 3.46% - 4.24% Expected term (in years) 5.00 - 10.00 5.00 - 10.00 Expected dividend yield 0% 0% Expected volatility 66.08% - 69.85% 64.86% - 70.50% The following table summarizes the stock option activity during the nine months ended September 30, 2024: Number of Weighted- Weighted Aggregate Outstanding at December 31, 2023 5,496,397 $ 6.54 Granted 1,530,445 3.69 Exercised (229,299) 3.19 Cancelled (201,140) 8.84 Outstanding at September 30, 2024 6,596,403 $ 4.45 7.44 $ 240,331 Vested and exercisable at September 30, 2024 3,664,815 $ 4.88 6.49 $ 43,303 For the three and nine months ended September 30, 2024 and 2023, the Company recognized share-based compensation expense on the accompanying condensed consolidated statements of operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 714,573 $ 657,652 1,959,834 1,864,462 General and administrative 925,543 821,508 2,816,789 2,222,085 Total $ 1,640,116 $ 1,479,160 $ 4,776,623 $ 4,086,547

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases In October 2020, the Company entered into an office lease (“Via Frontera Lease”) in San Diego, California with a lease term of 67 months. At the lease commencement date, a right-to-use asset and lease liability was recognized by the Company for $637,863. In January 2022, the Company exercised its option to terminate the Via Frontera Lease 20 months early . T he Company subsequently entered into a sublease of the Via Frontera Lease, the term of which commenced in March 2022. The lease and sublease terminated on October 1, 2023. The lease termination was accounted for as a lease modification which reduces the term of the existing lease and the Company adjusted the value of its right-of-use asset and operating lease liability by $347,739 using an incremental borrowing rate of approximately 6%. The sublease income was accounted for as a reduction of rent expense in the statement of operations. As part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California. One is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032; the second was for a 6,100 square feet of office and laboratory space under a lease that terminated on December 31, 2022; and the third was for a lease for 4,760 square feet of office and laboratory space under a lease that terminated on March 31, 2024. As a result, the Company recorded right-to-use assets and lease liabilities of $4,824,700 on the acquisition date of December 22, 2021. The Company currently also leases office space in Cambridge, Massachusetts and New York, New York, pursuant to short-term arrangements. The Cambridge lease is on a month-to-month basis, requiring one month’s notice before termination. The New York lease was renewed on July 17, 2024 to extend the lease term until February 28, 2025. These lease agreements include or included payments for lease and non-lease components. The Company has elected to not separate such components and these payments were recognized as rent expense. As of September 30, 2024, inclusive of the renewal outlined above, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, and New York, New York were $16,500 due in 2024 and $11,000 due in 2025. Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at September 30, 2024 were as follows: Amount Remainder of 2024 $ 183,546 2025 739,689 2026 761,877 2027 784,737 2028 808,278 Thereafter 2,874,231 Total future lease payments 6,152,358 Less: Imputed interest (1,911,332) Total lease liabilities $ 4,241,026 Lease liabilities $ 324,702 Lease liabilities, net of current portion 3,916,324 Total lease liabilities $ 4,241,026 Quantitative information regarding the Company’s leases for the nine months ended September 30, 2024 and 2023 is as follows: September 30, September 30, Lease costs: Operating lease cost $ 574,232 $ 675,743 Short-term lease cost 113,792 114,069 Sublease income (19,200) (133,530) Total lease costs $ 668,824 $ 656,282 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 549,000 $ 650,863 Operating cash flows from short-term leases 113,792 114,069 $ 662,792 $ 764,932 Weighted-average remaining lease term - operating leases 7.58 years 8.55 years Weighted-average discount rate - operating leases 10.0 % 10.0 % As the Company’s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Litigation From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its product candidates and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters. Clinical Research Contracts The Company may enter into contracts in the normal course of business with contract research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for the Company’s operating purposes. These contracts generally provide for termination with a 30-day notice.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (14,597,366)	$ (14,079,927)	$ (14,307,829)	$ (12,595,211)	$ (12,188,748)	$ (13,604,171)	$ (42,985,123)	$ (38,388,130)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB sets generally accepted accounting principles (“GAAP”) to ensure the condensed consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (“ASC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with GAAP and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with GAAP have been omitted from the unaudited interim condensed consolidated financial statements, as is permitted by such rules and regulations. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2023. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, operating results and cash flows. Revenues and net loss for any interim period are not necessarily indicative of future or annual results.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these condensed consolidated financial statements include but are not limited to: the accrued research and development expenses, the determination of fair value of stock-based awards, and the impairment of goodwill and intangible assets. Actual results may differ materially and adversely from these estimates.
Goodwill	Goodwill Goodwill represents the excess of the fair value of the acquiree over the recognized basis of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value. On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss. The Company performs its annual impairment test during the fourth quarter of each fiscal year. The Company performed an interim impairment analysis in the quarter ended June 30, 2024 as a result of the decline in market capitalization. Based on the step 1 analysis performed, the fair value of the reporting unit exceeded the carrying value on the valuation date and as a result there is no impairment pursuant to ASC 350 for the quarter ended June 30, 2024. There were no impairments identified for the year ended December 31, 2023 or for the three and nine months ended September 30, 2024 .
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional, and other third-party charges related to ongoing equity financings as deferred offering costs until fully consummated. These costs are to be recorded as a reduction of the offering’s proceeds which are recorded to additional paid-in capital within stockholders’ equity. Should the Company choose not to initiate such financing, the deferred offering costs would be immediately expensed as operating expenses. On August 10, 2022, the Company entered into an Equity Distribution Agreement (the “Sales Agreement”) with Piper Sandler & Co, (the “Sales Agent”) to sell shares of the Company’s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity offering program. Deferred offering costs associated with the Sales Agreement are reclassified to additional paid-in capital on a pro-rata basis when the Company completes offerings under the Sales Agreement. Any remaining deferred costs will be expensed to the statement of operations should the planned offering be abandoned. The Company had approximately $0.5 million of deferred offering costs as of September 30, 2024 and $0.3 million as of
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt certain new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280) (“ASU 2023-07”). The guidance in ASU 2023-07 expands prior reportable segment disclosure requirements by requiring entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and details of how the CODM uses financial reporting to assess their segment’s performance. The standard is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating this standard's potential impact on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this effective January 1, 2024 and there was no impact to the condensed consolidated financial statements.

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Marketable Securities	Marketable securities consisted of the following as of September 30, 2024 and December 31, 2023, respectively: September 30, 2024 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Assets: Current: U.S. Treasuries $ 3,467,888 $ 3,157 $ — $ 3,471,045 Commercial paper 1,979,620 1,490 — 1,981,110 Total marketable securities $ 5,447,508 $ 4,647 $ — $ 5,452,155 December 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Assets: Current: U.S. Treasuries $ 2,989,460 $ 430 $ — $ 2,989,890 Government securities 15,342,582 888 (2,902) 15,340,568 Commercial paper 7,928,122 1,301 (13) 7,929,410 Total marketable securities $ 26,260,164 $ 2,619 $ (2,915) $ 26,259,868

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Cash Equivalents and Marketable Securities	The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September 30, 2024: Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market $ 35,014,888 $ — $ — $ 35,014,888 U.S. Treasuries 1,748,407 — — 1,748,407 Government securities — 5,424,966 — 5,424,966 Commercial paper — 2,742,203 — 2,742,203 Total cash equivalents 36,763,295 8,167,169 — 44,930,464 Marketable securities: U.S. Treasuries $ 3,471,045 $ — $ — $ 3,471,045 Commercial paper — 1,981,110 — 1,981,110 Total marketable securities 3,471,045 1,981,110 — 5,452,155 Total cash equivalents and marketable securities $ 40,234,340 $ 10,148,279 $ — $ 50,382,619 The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2023: Level 1 Level 2 Level 3 Total Assets: Cash equivalents U.S. Treasuries $ 3,488,205 $ — $ — $ 3,488,205 Money market 50,122,883 — — 50,122,883 Commercial paper — 2,494,670 — 2,494,670 Government securities — 2,981,550 — 2,981,550 Total cash equivalents 53,611,088 5,476,220 — 59,087,308 Marketable securities: U.S. Treasuries $ 2,989,890 $ — $ — $ 2,989,890 Commercial paper — 7,929,410 — 7,929,410 Government securities — 15,340,568 — 15,340,568 Total marketable securities 2,989,890 23,269,978 — 26,259,868 Total cash equivalents and marketable securities $ 56,600,978 $ 28,746,198 $ — $ 85,347,176

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: September 30, December 31, Computer equipment $ 563,859 $ 550,861 Furniture and fixtures 98,628 98,628 Lab equipment 1,240,678 1,180,445 Leasehold improvements 298,941 298,941 Total 2,202,106 2,128,875 Accumulated depreciation/amortization (997,011) (728,293) Property and equipment, net $ 1,205,095 $ 1,400,582

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: September 30, December 31, Accrued professional services $ 319,462 $ 297,160 Accrued employee expenses 2,701,878 3,625,911 Accrued research and development expenses 1,502,456 1,146,398 Accrued other 69,029 104,491 Total $ 4,592,825 $ 5,173,960

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated at September 30, 2024 and September 30, 2023 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator: Net loss $ (14,597,366) $ (12,595,211) $ (42,985,123) $ (38,388,130) Denominator - basic and diluted: Weighted-average common shares outstanding, basic and diluted 29,841,883 29,266,309 29,622,670 28,129,005 Net loss per share - basic and diluted $ (0.49) $ (0.43) $ (1.45) $ (1.36)
Schedule of Potentially Dilutive Securities that have been Excluded from the Calculation of Diluted Net Loss Per Share	The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at September 30, 2024 and September 30, 2023: 2024 2023 Options to purchase common stock 6,596,403 5,490,165 Total shares of common stock equivalents 6,596,403 5,490,165

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions in its Application of the Black-Scholes Option Pricing Model for Grants	The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, 2024 2023 Weighted-average risk-free interest rate 3.93% - 4.82% 3.46% - 4.24% Expected term (in years) 5.00 - 10.00 5.00 - 10.00 Expected dividend yield 0% 0% Expected volatility 66.08% - 69.85% 64.86% - 70.50%
Summary of Stock Option Activity	The following table summarizes the stock option activity during the nine months ended September 30, 2024: Number of Weighted- Weighted Aggregate Outstanding at December 31, 2023 5,496,397 $ 6.54 Granted 1,530,445 3.69 Exercised (229,299) 3.19 Cancelled (201,140) 8.84 Outstanding at September 30, 2024 6,596,403 $ 4.45 7.44 $ 240,331 Vested and exercisable at September 30, 2024 3,664,815 $ 4.88 6.49 $ 43,303
Schedule of Recognized Share-based Compensation Expense Recognized	For the three and nine months ended September 30, 2024 and 2023, the Company recognized share-based compensation expense on the accompanying condensed consolidated statements of operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 714,573 $ 657,652 1,959,834 1,864,462 General and administrative 925,543 821,508 2,816,789 2,222,085 Total $ 1,640,116 $ 1,479,160 $ 4,776,623 $ 4,086,547

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturities of the Lease Liabilities Due	Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at September 30, 2024 were as follows: Amount Remainder of 2024 $ 183,546 2025 739,689 2026 761,877 2027 784,737 2028 808,278 Thereafter 2,874,231 Total future lease payments 6,152,358 Less: Imputed interest (1,911,332) Total lease liabilities $ 4,241,026 Lease liabilities $ 324,702 Lease liabilities, net of current portion 3,916,324 Total lease liabilities $ 4,241,026
Schedule of Quantitative Information Regarding the Company's Leases	Quantitative information regarding the Company’s leases for the nine months ended September 30, 2024 and 2023 is as follows: September 30, September 30, Lease costs: Operating lease cost $ 574,232 $ 675,743 Short-term lease cost 113,792 114,069 Sublease income (19,200) (133,530) Total lease costs $ 668,824 $ 656,282 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 549,000 $ 650,863 Operating cash flows from short-term leases 113,792 114,069 $ 662,792 $ 764,932 Weighted-average remaining lease term - operating leases 7.58 years 8.55 years Weighted-average discount rate - operating leases 10.0 % 10.0 %

Organization and Nature of Bu_2

Organization and Nature of Business (Details) - USD ($)				3 Months Ended						9 Months Ended
	Apr. 20, 2023	Aug. 10, 2022	Aug. 03, 2021	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Organization and Nature of Business
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs				$ 4,237,397				$ 27,996,235
Net loss				(14,597,366)	$ (14,079,927)	$ (14,307,829)	$ (12,595,211)	(12,188,748)	$ (13,604,171)	$ (42,985,123)	$ (38,388,130)
Accumulated deficit				$ (206,243,700)						$ (206,243,700)		$ (163,258,578)
IPO
Organization and Nature of Business
Aggregate net proceeds			$ 120,318,750
Offering costs			$ 2,124,317
At the market offering
Organization and Nature of Business
Shares issued (in shares)				1,318,752			0			1,318,752	0
Aggregate net proceeds				$ 4,200,000						$ 4,237,397	$ 0
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs		$ 50,000,000		$ 4,500,000						$ 4,500,000
Sale of stock (in dollars per share)				$ 3.27						$ 3.27
Underwriting Offering
Organization and Nature of Business
Sale of stock (in dollars per share)	$ 11
Shares sold (in shares)	2,727,273
Proceeds from company offering	$ 28,200,003
Sale of stock, proceeds before deducting offering costs payable	$ 203,768			$ 86,374				$ 203,768
Class A Common Stock
Organization and Nature of Business
Shares issued (in shares)			1,125,000
Common stock, par value per share (in dollars per share)				$ 0.001						$ 0.001		$ 0.001
Class A Common Stock | IPO
Organization and Nature of Business
Shares issued (in shares)			8,625,000
Class A Common Stock | At the market offering
Organization and Nature of Business
Common stock, par value per share (in dollars per share)		$ 0.001
Class A Common Stock | Underwriting Offering
Organization and Nature of Business
Common stock, par value per share (in dollars per share)	$ 0.001

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended	9 Months Ended	12 Months Ended
	Aug. 10, 2022	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Goodwill impairments		$ 0	$ 0	$ 0
Equity Distribution Agreement | Sandler and Co
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)	$ 0.001
Aggregate net proceeds	$ 50,000,000
Deferred offering costs		$ 500,000	$ 500,000	$ 300,000

Marketable Securities - Schedul

Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Marketable securities, current
Amortized Cost	$ 5,447,508	$ 26,260,164
Unrealized Gains	4,647	2,619
Unrealized Losses	0	(2,915)
Fair Value	5,452,155	26,259,868
U.S. Treasuries
Marketable securities, current
Amortized Cost	3,467,888	2,989,460
Unrealized Gains	3,157	430
Unrealized Losses	0	0
Fair Value	3,471,045	2,989,890
Government securities
Marketable securities, current
Amortized Cost		15,342,582
Unrealized Gains		888
Unrealized Losses		(2,902)
Fair Value		15,340,568
Commercial paper
Marketable securities, current
Amortized Cost	1,979,620	7,928,122
Unrealized Gains	1,490	1,301
Unrealized Losses	0	(13)
Fair Value	$ 1,981,110	$ 7,929,410

Marketable Securities - Narrati

Marketable Securities - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Credit loss related to short-term investments	$ 0	$ 0	$ 0	$ 0
Allowance for credit loss	$ 0		$ 0		$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities (Details) - Recurring - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Assets:
Total cash equivalents	$ 44,930,464	$ 59,087,308
Total marketable securities	5,452,155	26,259,868
Total cash equivalents and marketable securities	50,382,619	85,347,176
Money market
Assets:
Total cash equivalents	35,014,888	50,122,883
U.S. Treasuries
Assets:
Total cash equivalents	1,748,407	3,488,205
Total marketable securities	3,471,045	2,989,890
Government securities
Assets:
Total cash equivalents	5,424,966	2,981,550
Total marketable securities		15,340,568
Commercial paper
Assets:
Total cash equivalents	2,742,203	2,494,670
Total marketable securities	1,981,110	7,929,410
Level 1
Assets:
Total cash equivalents	36,763,295	53,611,088
Total marketable securities	3,471,045	2,989,890
Total cash equivalents and marketable securities	40,234,340	56,600,978
Level 1 | Money market
Assets:
Total cash equivalents	35,014,888	50,122,883
Level 1 | U.S. Treasuries
Assets:
Total cash equivalents	1,748,407	3,488,205
Total marketable securities	3,471,045	2,989,890
Level 1 | Government securities
Assets:
Total cash equivalents	0	0
Total marketable securities		0
Level 1 | Commercial paper
Assets:
Total cash equivalents	0	0
Total marketable securities	0	0
Level 2
Assets:
Total cash equivalents	8,167,169	5,476,220
Total marketable securities	1,981,110	23,269,978
Total cash equivalents and marketable securities	10,148,279	28,746,198
Level 2 | Money market
Assets:
Total cash equivalents	0	0
Level 2 | U.S. Treasuries
Assets:
Total cash equivalents	0	0
Total marketable securities	0	0
Level 2 | Government securities
Assets:
Total cash equivalents	5,424,966	2,981,550
Total marketable securities		15,340,568
Level 2 | Commercial paper
Assets:
Total cash equivalents	2,742,203	2,494,670
Total marketable securities	1,981,110	7,929,410
Level 3
Assets:
Total cash equivalents	0	0
Total marketable securities	0	0
Total cash equivalents and marketable securities	0	0
Level 3 | Money market
Assets:
Total cash equivalents	0	0
Level 3 | U.S. Treasuries
Assets:
Total cash equivalents	0	0
Total marketable securities	0	0
Level 3 | Government securities
Assets:
Total cash equivalents	0	0
Total marketable securities		0
Level 3 | Commercial paper
Assets:
Total cash equivalents	0	0
Total marketable securities	$ 0	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Fair Value Disclosures [Abstract]
Financial assets classified as Level 3	$ 0
Financial liabilities classified as Level 3	$ 0

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property and Equipment, net
Property and equipment, gross	$ 2,202,106	$ 2,128,875
Accumulated depreciation/amortization	(997,011)	(728,293)
Property and equipment, net	1,205,095	1,400,582
Computer equipment
Property and Equipment, net
Property and equipment, gross	563,859	550,861
Furniture and fixtures
Property and Equipment, net
Property and equipment, gross	98,628	98,628
Lab equipment
Property and Equipment, net
Property and equipment, gross	1,240,678	1,180,445
Leasehold improvements
Property and Equipment, net
Property and equipment, gross	$ 298,941	$ 298,941

Property and Equipment, net - N

Property and Equipment, net - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation/amortization expense	$ 88,949	$ 78,294	$ 269,691	$ 233,062

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued professional services	$ 319,462	$ 297,160
Accrued employee expenses	2,701,878	3,625,911
Accrued research and development expenses	1,502,456	1,146,398
Accrued other	69,029	104,491
Total	$ 4,592,825	$ 5,173,960

Common Stock - Class A Common S

Common Stock - Class A Common Stock (Details) - Class A Common Stock	9 Months Ended	12 Months Ended
	Sep. 30, 2024 Vote $ / shares shares	Dec. 31, 2023 Vote $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, par value per share (in dollars per share) | $ / shares	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	31,050,448	29,271,629
Common stock, shares outstanding (in shares)	31,050,448	29,271,629
Number of votes | Vote	1	1

Common Stock - Class B Common S

Common Stock - Class B Common Stock (Details) - Class B Common Stock	9 Months Ended	12 Months Ended
	Sep. 30, 2024 Vote $ / shares shares	Dec. 31, 2023 Vote $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value per share (in dollars per share) | $ / shares	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	0	0
Common stock, shares outstanding (in shares)	0	0
Number of votes | Vote	0	0

Common Stock - Equity Offerings

Common Stock - Equity Offerings (Details) - USD ($)				3 Months Ended			9 Months Ended
	Apr. 20, 2023	Aug. 10, 2022	Aug. 03, 2021	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class of Stock [Line Items]
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs				$ 4,237,397		$ 27,996,235
Equity Distribution Agreement | Sandler and Co
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)		$ 0.001
Aggregate net proceeds		$ 50,000,000
Deferred offering costs				$ 500,000			$ 500,000		$ 300,000
Class A Common Stock
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)				$ 0.001			$ 0.001		$ 0.001
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs (in shares)			1,125,000
At the market offering
Class of Stock [Line Items]
Percentage on gross proceeds from common stock sold for sales agent commission (as a percent)		3%
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs (in shares)				1,318,752	0		1,318,752	0
Sale of stock (in dollars per share)				$ 3.27			$ 3.27
Issuance of common stock upon public offering, net of commissions, underwriting discounts and issuance costs		$ 50,000,000		$ 4,500,000			$ 4,500,000
Aggregate net proceeds				4,200,000			$ 4,237,397	$ 0
At the market offering | Class A Common Stock
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)		$ 0.001
Aggregate gross sales proceeds		$ 50,000,000
Underwriting Offering
Class of Stock [Line Items]
Sale of stock (in dollars per share)	$ 11
Shares sold (in shares)	2,727,273
Proceeds from company offering	$ 28,200,003
Sale of stock, proceeds before deducting offering costs payable	$ 203,768			$ 86,374		$ 203,768
Underwriting Offering | Class A Common Stock
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)	$ 0.001
Maximum
Class of Stock [Line Items]
Aggregate amount		$ 200,000,000
Date of effective period (in years)		3 years

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net loss	$ (14,597,366)	$ (14,079,927)	$ (14,307,829)	$ (12,595,211)	$ (12,188,748)	$ (13,604,171)	$ (42,985,123)	$ (38,388,130)
Denominator - basic and diluted:
Weighted-average common shares outstanding, basic (in shares)	29,841,883			29,266,309			29,622,670	28,129,005
Weighted-average common shares outstanding, diluted (in shares)	29,841,883			29,266,309			29,622,670	28,129,005
Earnings per share:
Net loss per share, basic (in dollars per share)	$ (0.49)			$ (0.43)			$ (1.45)	$ (1.36)
Net loss per share, diluted (in dollars per share)	$ (0.49)			$ (0.43)			$ (1.45)	$ (1.36)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares of common stock equivalents (in shares)	6,596,403	5,490,165
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares of common stock equivalents (in shares)	6,596,403	5,490,165

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)			3 Months Ended		9 Months Ended
	May 21, 2024	Jul. 23, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	13 months
Granted (in shares)					1,530,445
Exercise price (in dollars per share)					$ 3.69
Outstanding options (in shares)			6,596,403		6,596,403		5,496,397
Stock-based compensation expense	$ 600,000		$ 1,640,116	$ 1,479,160	$ 4,776,623	$ 4,086,547
Grant date weighted average fair value (in dollars per share)					$ 3.69
General and Administrative and Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			84,000		$ 120,000
Vested Repriced Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	200,000
Unvested Repriced Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 400,000
Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)					4 years
Stock-based compensation expense			1,640,116	$ 1,479,160	$ 4,776,623	$ 4,086,547
Compensation expense remaining to be recognized			$ 11,544,508		$ 11,544,508
Compensation expense recognized over a weighted-average period (in years)					2 years 3 months 10 days
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)			1,388,539		1,388,539
Exercise price (in dollars per share)	$ 3.01
Outstanding options (in shares)	2,986,354
2021 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)		2,590,000
Aggregate number of shares outstanding (as a percent)		4%
2021 Plan | Maximum | Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		15,350,000
2021 ESPP | Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)		250,000	839,336		839,336
Aggregate number of shares outstanding (as a percent)		1%
Granted (in shares)					230,768
2021 ESPP | Maximum | Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		3,340,000

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average risk-free interest rate, minimum	3.93%	3.46%
Weighted-average risk-free interest rate, maximum	4.82%	4.24%
Expected dividend yield	0%	0%
Expected volatility, minimum	66.08%	64.86%
Expected volatility, maximum	69.85%	70.50%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years	10 years

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock option activity (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Number of Options
Outstanding at the beginning (in shares) | shares	5,496,397
Granted (in shares) | shares	1,530,445
Exercised (in shares) | shares	(229,299)
Cancelled (in shares) | shares	(201,140)
Outstanding at the ending (in shares) | shares	6,596,403
Vested and exercisable (in shares) | shares	3,664,815
Weighted- Average Exercise Price per Share
Weighted Average Exercise Price per Share Outstanding at the beginning (in dollars per share) | $ / shares	$ 6.54
Weighted Average Exercise Price per Share Granted (in dollars per share) | $ / shares	3.69
Weighted Average Exercise Price per Share Exercised (in dollars per share) | $ / shares	3.19
Weighted Average Exercise Price per Share Cancelled (in dollars per share) | $ / shares	8.84
Weighted Average Exercise Price per Share Outstanding at the ending (in dollars per share) | $ / shares	4.45
Weighted Average Exercise Price per Share Vested and exercisable (in dollars per share) | $ / shares	$ 4.88
Weighted Average Remaining Contractual Term (in Years)
Weighted Average Remaining Contractual Term (in Years)	7 years 5 months 8 days
Weighted Average Remaining Contractual Term, Vested and exercisable (in years)	6 years 5 months 26 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding | $	$ 240,331
Aggregate Intrinsic Value Vested and exercisable | $	$ 43,303

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)		3 Months Ended		9 Months Ended
	May 21, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 600,000	$ 1,640,116	$ 1,479,160	$ 4,776,623	$ 4,086,547
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		714,573	657,652	1,959,834	1,864,462
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 925,543	$ 821,508	$ 2,816,789	$ 2,222,085

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)	1 Months Ended	9 Months Ended
	Jan. 31, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 22, 2021 USD ($) ft² agreement	Oct. 31, 2020 USD ($)
Lessee, Lease, Description [Line Items]
Right-of-use assets, net		$ 3,748,565		$ 3,995,730
Decrease in right of use asset	$ 347,739
Lease liabilities	$ 347,739	221,934	$ 299,029
Incremental borrowing rate (as a percent)	6%
Lease liability		4,241,026
Remainder of 2024		183,546
Liability, to be paid 2025		$ 739,689
Notice period for contract termination		30 days
Lease Termination on April 30, 2032
Lessee, Lease, Description [Line Items]
Area of property under lease | ft²					38,613
Lease Termination on December 31, 2022
Lessee, Lease, Description [Line Items]
Area of property under lease | ft²					6,100
Lease Termination on March 31, 2024
Lessee, Lease, Description [Line Items]
Area of property under lease | ft²					4,760
BioArkive Inc
Lessee, Lease, Description [Line Items]
Right-of-use assets, net					$ 4,824,700
Number of lease obligations acquired | agreement					3
Lease liability					$ 4,824,700
2020 San Diego Lease
Lessee, Lease, Description [Line Items]
Lease term						67 months
Right-of-use assets, net						$ 637,863
Office and Laboratory Space in San Diego California
Lessee, Lease, Description [Line Items]
Period of lease modification	20 months
Office Space In Cambridge, Massachusetts, New York
Lessee, Lease, Description [Line Items]
Remainder of 2024		$ 16,500
Liability, to be paid 2025		$ 11,000

Commitments and Contingencies_2

Commitments and Contingencies - Maturities of the lease liabilities due (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2024	$ 183,546
2025	739,689
2026	761,877
2027	784,737
2028	808,278
Thereafter	2,874,231
Total future lease payments	6,152,358
Less: Imputed interest	(1,911,332)
Total lease liabilities	4,241,026
Lease liabilities	324,702	$ 300,107
Lease liabilities, net of current portion	$ 3,916,324	$ 4,162,852

Commitments and Contingencies_3

Commitments and Contingencies - Lease cost and contract termination (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Lease costs:
Operating lease cost	$ 574,232	$ 675,743
Short-term lease cost	113,792	114,069
Sublease income	(19,200)	(133,530)
Total lease costs	668,824	656,282
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	549,000	650,863
Operating cash flows from short-term leases	113,792	114,069
Total lease payment	$ 662,792	$ 764,932
Weighted-average remaining lease term - operating leases	7 years 6 months 29 days	8 years 6 months 18 days
Weighted-average discount rate - operating leases	10%	10%